Marksans Pharma Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: MARKSANS BSE: 524404

₹322.30

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #39 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Marksans Pharma Limited (this stock)	14,605	45.5	13.8%	93.4%	0.28%	69	12	50

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹14,514 Cr

EV / EBITDA

31.9x

EV / Sales

10.81x

Market cap / Sales

10.88x

Earnings yield

2.20%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 339 Cr, up 5.3% YoY.

↑ Positive

Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 69 Cr, up 43.7% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	321	90	69	₹1.5200
March 31, 2026	362	124	92	₹2.0300
Dec. 31, 2025	340	82	61	₹1.3400
Sept. 30, 2025	320	121	100	₹2.2000
June 30, 2025	320	64	48	₹1.0600
March 31, 2025	299	50	38	₹
Dec. 31, 2024	312	75	55	₹1.2200
Sept. 30, 2024	309	76	63	₹1.3900
June 30, 2024	255	42	32	₹0.7100
March 31, 2024	225	38	33	₹0.7300
Dec. 31, 2023	241	35	25	₹0.5600
Sept. 30, 2023	205	45	31	₹0.6900
June 30, 2023	182	54	44	₹0.9800

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23
Total income (before exceptional items)	339	389	356	379	322	334	340	263	237	243	221	215	157
Operating revenue	321	362	340	320	320	312	309	255	225	241	205	182	153
Other income	17	27	16	58	2	23	31	8	12	1	16	33	4
Operating expenses	239	256	264	248	250	252	256	213	191	199	167	155	130
Operating profit	82	106	75	72	70	60	52	41	34	42	37	27	23
Operating profit margin	25.6%	29.3%	22.2%	22.5%	21.9%	19.2%	16.9%	16.2%	15.1%	17.4%	18.2%	14.7%	14.8%
Depreciation	9	9	9	8	8	7	7	7	7	8	8	5	4
Interest	0	0	0	0	0	0	0	0	0	0	0	0	1
Exceptional items, gain / (loss)	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit before tax	90	124	82	121	64	75	76	42	38	35	45	54	23
Tax	21	32	21	22	16	19	13	10	5	9	13	10	5
Net profit	69	92	61	100	48	55	63	32	33	25	31	44	18
EPS	1.52	2.03	1.34	2.20	1.06	1.22	1.39	0.71	0.73	0.56	0.69	0.98	0.43
Net profit (TTM)	322	301	264	267	199	184	154	122	134	119	119	128	103
EPS (TTM)	7.09	6.63	5.82	5.87	4.38	4.05	3.39	2.69	2.96	2.66	2.73	3.04	2.53

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	1,341	392	301
March 31, 2025	1,174	243	188

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	26.4%	18.0%	1,445^†	—	915^†	716^†	701^†	631^†	434^†	440^†	—	—
Operating revenue	27.0%	17.5%	1,341	1,174	853^†	655^†	658^†	600^†	424^†	424^†	295^†	223^†
Other income	—	—	104^†	—	62^†	60^†	42^†	31^†	10^†	16^†	—	—
Operating expenses	—	—	1,018^†	—	713^†	563^†	—	486^†	362^†	369^†	258^†	189^†
Operating profit	52.1%	23.3%	324^†	—	140^†	92^†	—	114^†	62^†	56^†	36^†	33^†
Operating profit margin	—	—	24.1%^†	—	16.4%^†	14.0%^†	—	19.0%^†	14.6%^†	13.1%^†	12.4%^†	14.9%^†
Depreciation	—	—	34^†	—	29^†	17^†	—	15^†	12^†	9^†	12^†	15^†
Interest	—	—	1^†	—	1^†	4^†	—	5^†	7^†	7^†	8^†	3^†
Exceptional items, gain / (loss)	—	—	0^†	—	0^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†
Profit before tax	43.7%	25.8%	392	243	172^†	132^†	135^†	124^†	53^†	56^†	17^†	13^†
Tax	—	—	91^†	—	38^†	29^†	31^†	26^†	15^†	12^†	4^†	0^†
Net profit	43.0%	25.0%	301	188	134^†	103^†	104^†	98^†	38^†	44^†	12^†	12^†
EPS	37.9%	22.5%	6.63^†	—	2.96^†	2.53^†	—	2.40^†	0.93^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	24.1%^†	—	16.4%^†	14.0%^†	—	19.0%^†	14.6%^†	13.1%^†	12.4%^†	14.9%^†
EBIT margin	29.3%^†	—	20.3%^†	20.7%^†	—	21.6%^†	14.2%^†	14.8%^†	8.3%^†	7.2%^†
PBT margin	29.2%	20.7%	20.1%^†	20.2%^†	20.4%^†	20.7%^†	12.4%^†	13.2%^†	5.7%^†	5.7%^†
Net margin	22.4%	16.0%	15.7%^†	15.7%^†	15.8%^†	16.4%^†	8.9%^†	10.3%^†	4.2%^†	5.5%^†
Interest coverage	296.06x^†	—	174.98x^†	37.53x^†	—	24.26x^†	8.23x^†	9.53x^†	3.17x^†	4.66x^†
Dividend payout	12.1%^†	—	16.9%^†	9.9%^†	—	4.2%^†	5.4%^†	—	—	—
Earnings retention	87.9%^†	—	83.1%^†	90.1%^†	—	95.8%^†	94.6%^†	—	—	—
Current ratio	4.22x	3.13x	—	—	—	—	—	—	—	—
Quick ratio	3.61x	2.54x	—	—	—	—	—	—	—	—
Debt to equity	0.00x	0.00x	—	—	—	—	—	—	—	—
Return on equity	18.2%	13.6%	—	—	—	—	—	—	—	—
Return on assets	15.1%	10.7%	—	—	—	—	—	—	—	—
Return on capital employed	23.3%^†	—	—	—	—	—	—	—	—	—
Asset turnover	0.67x	0.67x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	211	-140	-39	49	162
March 31, 2025	31	17	-30	120	-89

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	1,994	1,652	1,607	0	0	1,309	310	91	369	189
March 31, 2025	1,755	1,383	1,338	0	0	1,082	346	60	354	205

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.